Team leader : Olivier Benveniste
The team lead by Prof. Olivier Benveniste is committed to perform translational medicine studies focused on muscle immunology (including primary inflammatory myopathies (myositis), and immune responses elicited by enzyme replacement therapy procedures targeting muscle lysosomial diseases).
Myositis projects
Auto-immune myopathies are a rare and heterogeneous acquired muscle diseases since both muscular and extra-muscular manifestations may differ, leading to identify subgroups of patients based on clinical phenotype and muscle pathology. Life-threatening complications still exist. The pathophysiology of these disabling diseases remains largely unknown. To date, most of these auto-immune myopathies are associated with newly described myositis specific auto-antibodies (MSA). Whereas each MSA is associated with a relatively homogenous clinical phenotype, nothing is known concerning the specificity of muscle pathology associated with a given MSA. In addition, the specificity of muscular immune response associated with a given MSA is not described as well.
Our goal is to revisit the classification, physiopathology and then treatment of the different inflammatory myopathies based on their MSA.
To achieve this goal and since the opening of the team, we have setting-up an e-CRF for myositis. We established the ethical management rules and obtained approval from ethical committee and CCTIRS. We launched this e-CRF in our center but also in 8 other centers in France. We started to perform patient characterization and phenotyping (998 patients are in the database in April 2015, and for 230 of them we already completed clinical/biological notably serological/imaging/pathology parameters). We hired a PhD student with a project in epidemiology to feed and analyse this database. In parallel, we established sample banking in “Myosites ADN-ARNthèque Serothèque Cellulothèque” (MASC study) (reference Codecoh: DC-2011-1445). Using these tools, we sharply characterize inflammatory responses of patients, effects of MSA on myoblasts primary cultures / tubes, or in vivo on mouse.
Lysosomial diseases and immune reactions elicited by enzyme replacement therapies
Pompe disease (PD) is an inherited metabolic myopathy caused by a deficiency of the lysosomal enzyme acid α-glucosidase (GAA). Enzyme replacement therapy (ERT) has improved the outcome of PD, however immune responses directed against infused recombinant GAA are not uncommon and in some cases prevent therapeutic efficacy. While it is clear that the development neutralizing antibodies to GAA is associated with a poor prognosis in infantile PD patients, in subjects with the milder form of the disease, the late-onset Pompe diseases (LOPD), immunity against GAA in ERT is poorly characterized both from an immunological and a clinical perspective.
The aim of the current study is to better characterize T cell responses to recombinant GAA in LOPD subjects with high vs. low antibody titers to the protein and to compare results in untreated LOPD subjects and healthy donors.
A similar approach is applied in Fabry disease, another lysosomal disorder eligible for ERT.
Team members
Olivier Benveniste, PU-PH, Team leader, Head of the Department of Internal Medicine et Clinical Immunology, Myositis National Network Coordinator
Yves Allenbach, MCU-PH, Co-team leader
Pascal Laforet, PH, Pompe disease National Network Coordinator
Olivier Lidove, PH, Fabry disease National Network Coordinator
Damien Amelin, Ingeneer
Akinori Uruha, Post-doc
Leandro Ladislau, Post-doc
Gaelle Dzangue-Tchoupou, Pre-doc
Kubéraka Mariampillai, Pre-doc
Wladimir Mauhin, Pre-doc
Last publications
- Rockette-Wagner B, Saygin D, Moghadam-Kia S, Oddis C, Landon-Cardinal O, Allenbach Y, Dzanko S, Koontz D, Neiman N, Aggarwal R. Reliability, validity and responsiveness of physical activity monitors in patients with inflammatory myopathy. Rheumatology (Oxford). 2021 Dec 1;60(12):5713-5723. doi: 10.1093/rheumatology/keab236.PMID: 33714992
- Lehmann LH, Cautela J, Palaskas N, Baik AH, Meijers WC, Allenbach Y, Alexandre J, Rassaf T, Müller OJ, Aras M, Asnani AH, Deswal A, Laufer-Perl M, Thuny F, Kerneis M, Hayek SS, Ederhy S, Salem JE, Moslehi JJ. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. JAMA Cardiol. 2021 Nov 1;6(11):1329-1337. doi: 10.1001/jamacardio.2021.2241.PMID: 34232253
- Marchiset A, Neuville M, Voiriot G, De Wolf J, Glorion M, Parquin F, Roux A, Guen ML, Allenbach Y, Zuber B, Cerf C; Foch Lung Transplant Group. High-Emergency Lung Transplantation for Interstitial Lung Disease Associated With Anti-MDA5 Dermatomyositis: A Case Report. Transplant Proc. 2021 Oct;53(8):2613-2615. doi: 10.1016/j.transproceed.2021.08.012. Epub 2021 Sep 10.PMID: 34511249
- Pawlitzki M, Nelke C, Rolfes L, Hasseli R, Tomaras S, Feist E, Schänzer A, Räuber S, Regner L, Preuße C, Allenbach Y, Benveniste O, Wiendl H, Stenzel W, Meuth SG, Ruck T. NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection. Cells. 2021 Sep 27;10(10):2551. doi: 10.3390/cells10102551.PMID: 34685530
- Ducatez F, Mauhin W, Boullier A, Pilon C, Pereira T, Aubert R, Benveniste O, Marret S, Lidove O, Bekri S, Tebani A. Parsing Fabry Disease Metabolic Plasticity Using Metabolomics. J Pers Med. 2021 Sep 8;11(9):898. doi: 10.3390/jpm11090898.PMID: 34575675
- Lioger B, Le Pendu C, Mounfaloti W, Allenbach Y.[Rhabdomyolysis and anemia in a 25 year-old man]. Rev Med Interne. 2021 Sep;42(9):669-671. doi: 10.1016/j.revmed.2021.08.007. Epub 2021 Aug 26.PMID: 34456071 French. No abstract available.
- Quirins M, Théaudin M, Cohen-Aubart F, Créange A, Mouthon L, Genty S, Kahn JE, Bérezné A, Rigolet A, Adams D, Adam C, Amoura Z, Benveniste O, Authier FJ, Guillevin L, Maisonobe T, Terrier B; French Vasculitis Study Group (FVSG). Nonsystemic vasculitic neuropathy: Presentation and long-term outcome from a French cohort of 50 patients. Autoimmun Rev. 2021 Aug;20(8):102874. doi: 10.1016/j.autrev.2021.102874. Epub 2021 Jun 9.PMID: 34118457 No abstract available.
- Phan F, Boussouar S, Lucidarme O, Zarai M, Salem JE, Kachenoura N, Bouazizi K, Charpentier E, Niati Y, Bekkaoui H, Amoura Z, Mathian A, Benveniste O, Cacoub P, Allenbach Y, Saadoun D, Lacorte JM, Fourati S, Laroche S, Hartemann A, Bourron O, Andreelli F, Redheuil A; COVID-19 APHP.SU Group. Cardiac adipose tissue volume and IL-6 level at admission are complementary predictors of severity and short-term mortality in COVID-19 diabetic patients. Cardiovasc Diabetol. 2021 Aug 12;20(1):165. doi: 10.1186/s12933-021-01327-1.PMID: 34384426 Free PMC article.
- Zahr N, Urien S, Llopis B, Pourcher V, Paccoud O, Bleibtreu A, Mayaux J, Gandjbakhch E, Hekimian G, Combes A, Benveniste O, Saadoun D, Allenbach Y, Pinna B, Cacoub P, Funck-Brentano C, Salem JE. Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. Therapie. 2021 Jul-Aug;76(4):285-295. doi: 10.1016/j.therap.2021.01.056. Epub 2021 Jan 28.PMID: 33558079 Free PMC article.
- Fer F, Allenbach Y, Benveniste O. [Myositis: From classification to diagnosis]. Rev Med Interne. 2021 Jun;42(6):392-400. doi: 10.1016/j.revmed.2020.10.379. Epub 2020 Nov 25.PMID: 33248855 French.
- Guetta M, Kas A, Aouidad A, Soret M, Allenbach Y, Bordonné M, Oppetit A, Raffin M, Psimaras D, Cohen D, Consoli A. Relevance of Brain 18F-FDG PET Imaging in Probable Seronegative Encephalitis With Catatonia: A Case Report. Front Psychiatry. 2021 Jun 9;12:685711. doi: 10.3389/fpsyt.2021.685711. eCollection 2021.PMID: 34177668 Free PMC article.
- Fenioux C, Allenbach Y, Vozy A, Salem JÉ, Maalouf G, Vieira M, Le Joncour A, Benveniste O, Saadoun D, Frère C, Campedel L, Salem P, Gligorov J, Funck-Brentano C, Cacoub P, Gougis P. [Differences of characteristics and outcomes between cancer patients and patients with no active cancer hospitalised for a SARS-CoV-2 infection]. Bull Cancer. 2021 Jun;108(6):581-588. doi: 10.1016/j.bulcan.2021.03.004. Epub 2021 Mar 20.PMID: 33966886 Free PMC article. French.
- Peyre M, Zahr N, Riller Q, Cohen-Aubart F, Allenbach Y, Benveniste O, Hervier B. Mycophenolic acid area under the curve in patients with inflammatory myopathies. Rheumatology (Oxford). 2021 Jun 18;60(6):3026-3028. doi: 10.1093/rheumatology/keab167.PMID: 33629113 No abstract available.
- Reyngoudt H, Marty B, Boisserie JM, Le Louër J, Koumako C, Baudin PY, Wong B, Stojkovic T, Béhin A, Gidaro T, Allenbach Y, Benveniste O, Servais L, Carlier PG. Global versus individual muscle segmentation to assess quantitative MRI-based fat fraction changes in neuromuscular diseases. Eur Radiol. 2021 Jun;31(6):4264-4276. doi: 10.1007/s00330-020-07487-0. Epub 2020 Nov 21.PMID: 33219846
- Malartre S, Bachasson D, Mercy G, Sarkis E, Anquetil C, Benveniste O, Allenbach Y. MRI and muscle imaging for idiopathic inflammatory myopathies. Brain Pathol. 2021 May;31(3):e12954. doi: 10.1111/bpa.12954.PMID: 34043260 Free PMC article.
- Preusse C, Eede P, Heinzeling L, Freitag K, Koll R, Froehlich W, Schneider U, Allenbach Y, Benveniste O, Schänzer A, Goebel HH, Stenzel W, Radke J. NanoString technology distinguishes anti-TIF-1γ+ from anti-Mi-2+ dermatomyositis patients. Brain Pathol. 2021 May;31(3):e12957. doi: 10.1111/bpa.12957.PMID: 34043263 Free PMC article.
- Bolko L, Jiang W, Tawara N, Landon-Cardinal O, Anquetil C, Benveniste O, Allenbach Y. The role of interferons type I, II and III in myositis: A review. Brain Pathol. 2021 May;31(3):e12955. doi: 10.1111/bpa.12955.PMID: 34043262 Free PMC article.
- Nguyen A, Repesse Y, Ebbo M, Allenbach Y, Benveniste O, Vallat JM, Magy L, Deshayes S, Maigné G, de Boysson H, Karnam A, Delignat S, Lacroix-Desmazes S, Bayry J, Aouba A. IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans. Clin Exp Immunol. 2021 May;204(2):258-266. doi: 10.1111/cei.13580. Epub 2021 Feb 22.PMID: 33512707
- Toquet S, Granger B, Uzunhan Y, Mariampillai K, Nunes H, Benveniste O, Allenbach Y. The seasonality of Dermatomyositis associated with anti-MDA5 antibody: An argument for a respiratory viral trigger. Autoimmun Rev. 2021 Apr;20(4):102788. doi: 10.1016/j.autrev.2021.102788. Epub 2021 Feb 18.PMID: 33609802 No abstract available.
- Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; RESILIENT Study Extension Group. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology. 2021 Mar 23;96(12):e1595-e1607. doi: 10.1212/WNL.0000000000011626. Epub 2021 Feb 17.PMID: 33597289 Clinical Trial.
- Le Joncour A, Frere C, Martin-Toutain I, Gougis P, Ghillani-Dalbin P, Maalouf G, Vieira M, Marcelin AG, Salem JE, Allenbach Y, Saadoun D, Benveniste O, Cacoub P. Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. Autoimmun Rev. 2021 Feb;20(2):102729. doi: 10.1016/j.autrev.2020.102729. Epub 2020 Dec 13.PMID: 33321245
- Bachasson D, Ayaz AC, Mosso J, Canal A, Boisserie JM, Araujo ECA, Benveniste O, Reyngoudt H, Marty B, Carlier PG, Hogrel JY. Lean regional muscle volume estimates using explanatory bioelectrical models in healthy subjects and patients with muscle wasting. J Cachexia Sarcopenia Muscle. 2021 Feb;12(1):39-51. doi: 10.1002/jcsm.12656. Epub 2020 Dec 29.PMID: 33377299
- Geraud A, Gougis P, Vozy A, Anquetil C, Allenbach Y, Romano E, Funck-Brentano E, Moslehi JJ, Johnson DB, Salem JE. Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:85-112. doi: 10.1146/annurev-pharmtox-022820-093805. Epub 2020 Sep 1.PMID: 32871087 Review.
- Vieira M, Maalouf G, Hasan M, Le Joncour A, Karkeni E, Idir M, Amelin D, Salem JE, Gougis P, Lacorte JM, Biard L, Benveniste O, Cacoub P, Saadoun D, Allenbach Y; behalf of DIMICOVID. Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on “Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome” by Quartuccio et al. Joint Bone Spine. 2020;87:191-93. Joint Bone Spine. 2021 Jan;88(1):105074. doi: 10.1016/j.jbspin.2020.09.006. Epub 2020 Sep 17.PMID: 32950702
- Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23.PMID: 32327425